In Silico Drug Design: Finally Ready For Prime Time?
Executive Summary
Advances in computational power and in the application of quantum mechanics to drug modeling are rekindling interest in in silico drug design. The prize is a steep reduction in the cost of discovery and an increase in the quality of lead candidates.
You may also be interested in...
Can Artificial Intelligence Help Find Better Medicines?
Artificial intelligence won’t transform pharma R&D, at least not anytime soon. But it is already impacting health care delivery and clinical trials.
Verseon Claims Major Move In Drug Design, Will Enter Clinic Within A Year
The Fremont, California-based company has developed a computer-driven discovery platform that can model drug-protein interactions with unparalleled accuracy but can also generate synthetic pathways for its drug candidates.
Mesoblast’s Late-Stage Pipeline Could Be Game Changing: Are Investors Paying Attention?
Mesenchymal cell specialist Mesoblast came back from a near-death experience in 2016 when Teva returned a key asset. But recent success in a Phase III trial in acute GVHD has brought it some attention. Now it needs to repeat the achievement in advanced heart failure and find a partner for its burgeoning pipeline.